Sensei Biotherapeutics将参与Canaccord Genuity在肿瘤学领域的虚拟会议-动脉网

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

GlobeNewswire 等信源发布 2025-04-02 07:30



可切换为仅中文







BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will participate in the New Radiotherapy and Targeted Therapy Approaches panel at the Canaccord Genuity Horizons in Oncology Virtual Conference on Monday, April 7 at 2:00 p.m.

波士顿，2025年4月2日（环球新闻社）——Sensei Biotherapeutics, Inc.（纳斯达克股票代码：SNSE），一家专注于为癌症患者发现和开发下一代疗法的临床阶段生物技术公司，今天宣布，公司总裁兼首席执行官约翰·塞莱比将参加于4月7日星期一下午2:00举行的Canaccord Genuity肿瘤学视野虚拟会议中的“新放射治疗与靶向治疗进展”专题讨论。

ET..

外星人..

About Sensei Biotherapeutics

关于Sensei Biotherapeutics

Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors.

Sensei Biotherapeutics（纳斯达克股票代码：SNSE）是一家处于临床阶段的生物技术公司，专注于为癌症患者发现和开发下一代疗法。通过其TMAb™（肿瘤微环境激活生物制剂）平台，Sensei开发条件性激活疗法，旨在肿瘤微环境中选择性地禁用免疫抑制信号或激活免疫刺激信号，从而释放T细胞对肿瘤的攻击能力。

Sensei’s lead product candidate is solnerstotug, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. For more information, please visit .

Sensei的主要候选产品是solnerstotug，这是一种条件活性抗体，旨在低pH值的肿瘤微环境中选择性阻断T细胞激活的V结构域Ig抑制因子（VISTA）检查点，VISTA通过与受体PSGL-1结合在该环境中充当T细胞的抑制因子。欲了解更多信息，请访问。

www.senseibio.com

, and follow the company on X @SenseiBio and

，并在X上关注公司 @SenseiBio 和

领英

。

Investor Contact:

投资者联系方式：

Michael Biega

迈克尔·别加

Senior Director, Investor Relations

投资者关系高级总监